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Background: Multiple Sclerosis Partners Advancing Technology and Health Solutions
(MS PATHS) is the first example of a learning health system in multiple sclerosis (MS). This
paper describes the initial implementation of MS PATHS and initial patient characteristics.
Methods: MS PATHS is an ongoing initiative conducted in 10 healthcare institutions
in three countries, each contributing standardized information acquired during routine
care. Institutional participation required the following: active MS patient census of
≥500, at least one Siemens 3T magnetic resonance imaging scanner, and willingness
to standardize patient assessments, share standardized data for research, and offer
universal enrolment to capture a representative sample. The eligible participants have
diagnosis of MS, including clinically isolated syndrome, and consent for sharing
pseudonymized data for research. MS PATHS incorporates a self-administered patient
assessment tool, the Multiple Sclerosis Performance Test, to collect a structured history,
patient-reported outcomes, and quantitative testing of cognition, vision, dexterity, and
walking speed. Brain magnetic resonance imaging is acquired using standardized
acquisition sequences on Siemens 3T scanners. Quantitative measures of brain volume
and lesion load are obtained. Using a separate consent, the patients contribute DNA,
RNA, and serum for future research. The clinicians retain complete autonomy in using
MS PATHS data in patient care. A shared governance model ensures transparent data
and sample access for research.
Results: As of August 5, 2019, MS PATHS enrolment included participants
(n = 16,568) with broad ranges of disease subtypes, duration, and severity. Overall,
Mowry et al. Learning Health System in MS
14,643 (88.4%) participants contributed data at one or more time points. The
average patient contributed 15.6 person-months of follow-up (95% CI: 15.5–15.8);
overall, 166,158 person-months of follow-up have been accumulated. Those with
relapsing–remitting MS demonstrated more demographic heterogeneity than the
participants in six randomized phase 3MS treatment trials. Across sites, a significant
variation was observed in the follow-up frequency and the patterns of disease-modifying
therapy use.
Conclusions: Through digital health technology, it is feasible to collect standardized,
quantitative, and interpretable data from each patient in busy MS practices, facilitating
the merger of research and patient care. This approach holds promise for data-driven
clinical decisions and accelerated systematic learning.
Keywords: learning health system, multiple sclerosis, MS PATHS, digital health technology, standardized brain
magnetic resonance imaging
INTRODUCTION
The multiple sclerosis (MS) treatment landscape has experienced
a dramatic evolution over the past two decades; there
are now 16 approved disease-modifying therapies (DMTs).
Approaches to personalized medicine in MS, however, have
not kept pace. Defining disease prognosis, treatment outcomes,
monitoring treatment response, and determining optimal
treatment sequencing remain variable and somewhat subjective
in MS practice. Personalized medicine efforts have focused both
on identifying informative patient phenotypes (1) and effectively
integrating and visualizing individual patient data (2).
The rigorous collection and analysis of real-world data may
accelerate the development of personalized medicine in MS and
address some of these gaps (3–5). Opportunities and challenges
related to data pooling and data standardization in MS were
recognized by early pioneers, beginning decades ago (6, 7), and
recent progress has been summarized (8, 9). These efforts have
ushered in an era of data standardization and pooling in an
attempt to extend systematic learning beyond structured research
protocols to more representative real-world populations. For
maximum impact, data should include standardized and
quantitative clinical, radiologic, and biological phenotyping from
a heterogeneous population representative of the diversity of
patients with MS seen in everyday clinical practice.
The learning health system (LHS) model, as proposed by
the Institute of Medicine, outlines a method to enable broad-
scale quantitative patient phenotyping through the merging
of clinical research and healthcare delivery (4, 10). The LHS
Abbreviations: DMT, disease-modifying therapy; EMR, electronic medical
record; FLAIR, fluid-attenuated inversion recovery; IQR, interquartile range; IT,
information technology; LHS, learning health system; MPRAGE, magnetization-
prepared rapid gradient-echo imaging; MRI, magnetic resonance imaging; MS,
multiple sclerosis; MS PATHS, Multiple Sclerosis Partners Advancing Technology
and Health Solutions; MSPT, Multiple Sclerosis Performance Test; NA, not
applicable; Neuro-QoL, Quality of Life in Neurological Disorders; PPMS, primary
progressive multiple sclerosis; PRMS, progressive relapsing multiple sclerosis;
RCT, randomized controlled clinical trial; RRMS, relapsing-remitting multiple
sclerosis; SPMS, secondary progressive multiple sclerosis.
(also known as evidence-generating medicine) seeks to produce
better outcomes and research based on real-time data acquisition
(10). The tenets of the LHS concept include collection of
standardized, meaningful data on every patient seeking care,
increased engagement of patients in the process of care, use of
quantitative data for clinical decision-making, and aggregation
of data from populations for systematic learning (10). The LHS
represents a culture of continuous learning, feeding insights
back into care delivery to continuously reanalyze, revalidate, and
improve outcomes.
The current report describes the first LHS in MS, Multiple
Sclerosis Partners Advancing Technology and Health Solutions
(MS PATHS). In MS PATHS, quantitative clinical and imaging
data are collected in a standardized manner for each patient as
part of routine care. Data are collected as part of the patient’s
clinical evaluation, while—with a patient’s permission—the data
are pseudonymized and aggregated for systematic learning.
The program leverages technology and patient engagement to
automate data collection and analysis, minimizing the burden on
the care system and providers. The specific goals of MS PATHS
are to better understand the disease, identify the predictors of
therapeutic responses, define and measure outcomes during the
course of care, and develop approaches to personalized medicine.
We aim to demonstrate the feasibility of implementing the key
features of an LHS in MS by describing the patient population
enrolled in MS PATHS to date, initial data completion rates,
differences between MS PATHS and typical MS clinical trial
patients, heterogeneity of practice across the network, and
utilization of the research data.
MATERIALS AND METHODS
Initial Design
MS PATHS is a collaborative network of healthcare institutions
that have standardized elements of their clinical assessments and
collaborated with Biogen to implement a centralized database
for research purposes. This network was designed based on the
guiding principles described in Table 1. In 2014, a group of
stakeholders from Cleveland Clinic, Johns Hopkins University,
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TABLE 1 | Guiding principles for MS PATHS.
Engage all healthcare providers and nearly all patients with MS in a healthcare
institution
Standardize, quantify, and maximize data collected as part of standard of care
• Identify key data points needed to interpret test results, achieve practice
standards/meaningful use, and enable the generation of new
clinical knowledge
Leverage technology to enable data collection in clinical practice
• Make it possible to collect data on all participating patients, which is too time
consuming using traditional research methods
• Leverage patient-reported data to the greatest extent possible
• Make MSPT data available at the point of care and simultaneously aggregate
data for learning
Collect data outside of standard of care via separately consented substudies
Ensure transparent governance by multi-stakeholder group
Become recognized as meaningful by patients, providers, payers, and other
stakeholders
MS, multiple sclerosis; MS PATHS, Multiple Sclerosis Partners Advancing Technology and
Health Solutions; MSPT, Multiple Sclerosis Performance Test.
New York University, and Biogen began the planning process
to best design the tools, systems, and governance needed for an
LHS in MS.
Methods for standardized clinical and imaging data collection
that do not increase the burden on providers or generate
significant incremental cost were an important aspect of the
planning process. Technology was developed to allow patient
self-administered clinical assessment, resulting in standardized,
high-quality clinical data. Technician-based testing—specifically,
Multiple Sclerosis Functional Composite testing—was adapted to
a series of patient self-administered iPad-based tests to provide
quantitative data related to processing speed, low-contrast visual
acuity, manual dexterity, and walking speed (11). This was done
in order to facilitate the neuroperformance testing for every
patient with MS, even in a busy clinical practice (12–14). The
iPad-based clinical assessment tool, called the Multiple Sclerosis
Performance Test (MSPT), also enabled the collection of a
structured patient history.
Because the clinical assessment was patient self-administered,
there are differences between the MSPT and the physician-
derived measures used in clinical trials and traditional MS
practice registries. Neurologist-determined relapses and
Expanded Disability Status Scale were replaced by patient-
reported relapse and Patient Determined Disease Steps. Prior
studies support the validity of self-reported relapses (15, 16)
and showed a strong correlation between Patient Determined
Disease Steps and Expanded Disability Status Scale (17–19). The
MSPT also enabled the collection of quality-of-life data. The
Quality of Life in Neurological Disorders (Neuro-QoL) measure
was selected as a standardized, well-validated patient-reported
outcome instrument (20–22). The computer-adapted version
of Neuro-QoL was incorporated into the MSPT to minimize
administration time.
Two standardized magnetic resonance imaging (MRI)
acquisition sequences were incorporated into routine MS
imaging protocols to enable the reliable calculation of
brain atrophy and lesions at the point of care. Through a
collaboration with Siemens Healthineers, a software prototype
is currently in development, with a focus on workflow
integration and performance adequate for individual patient
clinical decision-making.
To enable translational research, an MS PATHS research
substudy was implemented to enable the collection of blood
samples under a research protocol that could be linked to the
standardized clinical and imaging data for future analyses.
Participating Healthcare Institutions
To be eligible for MS PATHS, the participating healthcare
institutions had to have an MS center with an active census of
≥500 patients that routinely used functional measures and MRI
in their clinical practice and a willingness to further standardize
aspects of their clinical and radiological assessments. In addition,
each participating healthcare institution had to have at least
one Siemens 3T MRI scanner available for clinical use. Each
participating center had to be willing to implement a centralized
health information exchange architecture to transfer the data to a
research database and obtain approval of the project protocol by
the institutional review board or ethics committee, information
technology (IT) security, and/or data privacy committee and
agree to adhere to Good Clinical Practice and ethical principles
as outlined in the Declaration of Helsinki. The participating
healthcare institutions of each investigator receive financial
compensation for data shared and biosamples collected as part
of this program based on fair market value.
Patients
Patients with a confirmed diagnosis of MS, including clinically
isolated syndrome, and the ability to understand the purpose and
the risks of the project are eligible to enroll in MS PATHS. In
contrast with a traditional prospective observational study, the
sites in MS PATHS agree to adopt the outlined standard of care,
and the patients provide authorization for the use of protected
health information in accordance with national and local subject
privacy regulations. Authorization format was determined by
the local institutional review board or ethics committee and
ranges from the use of a standard medical information privacy
waiver (four institutions) to an oral consent (one institution) to
a full informed consent (five institutions). The investigators and
research coordinators are encouraged to invite all patients at each
MS center to participate. At steady state, the network aims to have
80% of the MS patients at each participating MS center enrolled
in MS PATHS.
Procedures
Upon enrollment, the patients are assigned a unique MS PATHS
identification number that acts as the patient identifier in the
LHS. This allows linkage of pseudonymized data from different
sources for the same patient. The authorization form allows
for prospective data sharing as well as sharing of data from 12
months before the date of consent.
The data elements collected routinely for patients in MS
PATHS are listed in Table 2. Clinical data are collected using
the MSPT. In addition, structured clinical data are shared from
electronic medical records at each institution. Imaging data
Frontiers in Neurology | www.frontiersin.org 3 August 2020 | Volume 11 | Article 632
Mowry et al. Learning Health System in MS
TABLE 2 | Current data elements collected in the MS PATHS learning health
system.






• Employment status (MSPT)
• Insurance coverage type (MSPT and EMR)
• Living situation (MSPT)
• Employment status (MSPT)
• Dominant hand (MSPT)
MS and other medical history (MSPT and EMR)
• MS subtype (MSPT)
• Age at first MS symptom onset (MSPT)
• Age at MS diagnosis (MSPT)
• Mobility aid use (MSPT)
• Smoking status (EMR)
Physical and laboratory assessments (EMR)
• Weight and height
• Body mass index
• Blood pressure
• Laboratory test values
Medications (MSPT and EMR)
• Patient self-reported use of MS disease-modifying therapy (MSPT)
• Medication list (EMR)
Patient-reported outcomes and tests (MSPT)
• Patient-reported relapses
• Patient Determined Disease Steps
• Neuro-QoL
◦ Mental




‚Emotional and behavioral dyscontrol
‚Positive affect and well-being




‚Lower extremity function (mobility)
‚Sleep disturbance
‚Upper extremity function (fine motor, ADL)
• Neuroperformance testing
◦ Walking Speed Test
◦ Processing speed test
◦ Manual dexterity test
◦ Contrast sensitivity test
MRI-related data
• 3D T1 and 3D FLAIR MRI
• Radiologist report of number of new or enlarging T2 lesions (EMR)
• Radiologist report of number of enhancing T2 lesions (EMR)
• Quantitative brain volume metrics*
• Quantitative T2 lesion metrics*
3D, three-dimensional; ADL, activities of daily living; EMR, electronic medical record;
FLAIR, fluid-attenuated inversion recovery; MRI, magnetic resonance imaging; MS,
multiple sclerosis; MSPT, Multiple Sclerosis Performance Test; Neuro-QoL, Quality of Life
in Neurological Disorders.
*Under development.
TABLE 3 | Standardized Siemens 3T brain MRI sequence parameters for MS
PATHS.




Resolution (mm) 1 × 1 × 1 1 × 1 × 1
Field of view 256 × 256 × 176 256 × 256 × 176
Orientation Sagittal Sagittal
Total acquisition time (min:s) 6:27 5:12
Repetition time (ms) 5,000 2,300
Echo time (ms) 392 2.96
Inversion time (ms) 1,800 900
3D, three-dimensional; FLAIR, fluid-attenuated inversion recovery; MPRAGE,
magnetization-prepared rapid gradient-echo imaging; MRI, magnetic resonance imaging;
ms, milliseconds; MS PATHS, Multiple Sclerosis Partners Advancing Technology and
Health Solutions.
include brain MRIs acquired using two standardized sequences
(three-dimensional fluid-attenuated inversion recovery and
three-dimensional T1 acquired on Siemens 3T scanners;
Table 3), information from radiology reports, and quantitative
measures of brain atrophy and lesion metrics derived from an
image analysis software prototype.
Data collected during patient care visits can also be linked
to substudies. Each substudy requires a separate protocol and
informed consent to allow for research assessments or procedures
and for the linkage of the substudy data with patient care data.
An example is an ongoing biorepository substudy that collects
a one-time blood sample for future genomic analyses (10ml for
adult patients and 6ml for pediatric patients) and repeated blood
samples for future biomarker analyses (33ml for adult patients
and 13.5ml for pediatric patients) not more frequently than every
6 months. The clinical phenotyping information for any genetic
or biomarker analyses will be derived from the routine clinical
care data that are shared as part of MS PATHS.
Governance
The governance for MS PATHS requires a structure and a
process that:
(1) Are fair, transparent, and compliant for all
participating organizations;
(2) Assure confidence from all participating organizations;
(3) Foster collaboration;
(4) Reinforce the clinical and research integrity of participating
healthcare institutions;
(5) Ensure that all participating organizations have sufficient
freedom to operate; and
(6) Foster innovation, limit risk, and enable long-term success.
A steering committee was tasked with:
(1) Providing strategic and operational guidance;
(2) Setting the MS PATHS scientific strategy;
(3) Creating and overseeing data and sample access rules;
(4) Monitoring performance; and
(5) Providing other oversight activities as needed.
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The steering committee consists of six representatives from
participating healthcare institutions and one representative
from Biogen. Three steering committee seats are reserved for
investigators from the institutions that collaborated with Biogen
on the initial planning process (Cleveland Clinic Foundation,
Johns Hopkins University, and New York University), and one
seat each is designated for an additional US healthcare institution,
an EU healthcare institution, and a radiologist in MS PATHS.
The steering committee governs a set of data and sample
access subcommittees responsible for approving requests for
MS PATHS data and samples. The healthcare institutions
and Biogen each have separate data and sample access
committees. Biogen employees do not sit on the healthcare
institution committees and vice versa. Separate subcommittees
for Biogen and participating healthcare institutions were set up
to ensure the independence of research led by the participating
healthcare institutions. The healthcare institution and Biogen
subcommittees operate under the same procedures, and all
approved uses of the data or the samples are posted on the MS
PATHS research website, which is accessible to Biogen and the
participating healthcare institutions to ensure transparency and
promote collaboration. In addition to approving data or sample
requests, these subcommittees are also responsible for reviewing
resulting presentations or publications to ensure alignment with
the original request. Biogen, as the sponsor, has no role in
writing or editing publications unless a Biogen employee is
a co-author.
Standardization
Participating healthcare institutions have implemented the
MSPT (11, 13, 14), an iPad-based medical assessment tool that
quantifies major MS-associated motor, visual, and cognitive
symptoms and quality-of-life outcomes. The MSPT incorporates
a structured patient history (gathers the patient’s relevant
demographic and socioeconomic information, MS history, MS
treatment information, and self-reported disability using the
Patient Determined Disease Steps) (17–19), 12 subscales of
the Neuro-QoL (20–22), and an electronic adaptation of the
Multiple Sclerosis Functional Composite (23). The adapted
Multiple Sclerosis Functional Composite includes a processing
speed test that is similar to the Symbol Digit Modalities
Test; a manual dexterity test, similar to the 9-Hole Peg Test;
a contrast sensitivity test, similar to the Sloan low-contrast
visual acuity test; and a 25-foot walking speed test, similar
to the Timed 25-Foot Walk. The MSPT is administered
during routine clinical visits, typically prior to meeting with
the healthcare provider. Depending on the institution, the
results are immediately available to the healthcare provider
via the patient’s electronic medical record or via a results
screen on the MSPT. The processing speed test, manual
dexterity test, contrast sensitivity test, and 25-foot walking
speed test demonstrate reliability, validity, and sensitivity to MS
outcomes (13, 14).
In MS PATHS, the participating healthcare institutions
collaborate with Biogen and Siemens Healthineers to implement
two highly standardized MRI acquisition sequences (a three-
dimensional magnetization-prepared rapid gradient-echo
imaging and three-dimensional fluid-attenuated inversion
recovery) that are readily available product sequences and
consistent with recent MS imaging guidelines (24). The
participating healthcare institutions have also implemented
standardized fields in the radiology report for assessment of
new or enlarging T2 lesions and contrast-enhancing lesions
(if applicable).
Health Information Exchange Architecture
MS PATHS is enabled by health IT that supports the secure
transfer, processing, and harmonization of clinical data for
research purposes. Similar to the hub-and-spoke model of data
transfer in health information exchanges, clinical source systems
such as the electronic medical record systems at participating
healthcare institutions (the spokes) will send data through a series
of intermediary systems before the data are passed through to the
central MS PATHS research database (also known as the LHS).
Each participating institution is supported by a separate
gateway that is responsible for applying consent logic to
incoming data and then conducting any needed format
transformations to enable ingestion by a central data broker.
The two data brokers, one for the United States and one for
the European Union, manage a patient registration and consent
index as well as a de-identification tool that pseudonymizes data.
Patient data other than consent and registration information are
deleted from each broker after five business days.
Biogen has contracted with an IT vendor to act as a
trusted third party to build and operate the MS PATHS
gateways and data brokers. This IT vendor is responsible for
protecting and processing identifiable patient data before they are
pseudonymized and sent to the LHS.
In the United States, the vendor has entered into business
associate agreements with each participating healthcare
institution. Biogen does not have access to the data in either
broker. In the European Union, each healthcare institution has
contracted with an additional IT vendor to serve as the initial
intermediary prior to the edge gateway. The EU IT vendor
completes an initial pseudonymization of the data before they
are transferred to an institution’s gateway and subsequently to
the EU broker. Once the data are pseudonymized in a broker,
they are transferred to the LHS. The LHS is logically isolated
from the brokers so that both Biogen and researchers from
participating healthcare institutions do not have access to
identifiable patient data.
In the LHS, data are harmonized using industry-accepted
clinical terminology standards such as SNOMED, Logical
Observation Identifiers Names and Codes, RxNorm, National
Drug Code, and International Statistical Classification of Diseases
and Related Health Problems. The LHS data are available to
be requested for research purposes by any researcher at a
participating healthcare institution or at Biogen.
Statistical Analysis
Descriptive analyses were used to describe MS PATHS patient
characteristics at the time of a patient’s initial MSPT assessment.
Continuous variables were reported asmean (SD) and categorical
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TABLE 4 | Patient demographic and clinical characteristics at initial assessment.
Characteristic* Value
Mean (SD) age (years)† 47.0 (12.4)
Female, n (%)‡ 10,712 (73.2)
Race/area of origin, n (%)‡
United States—race 11,236 (76.7)
White 8,933 (79.5)
Black or African American 1,419 (12.6)
Asian 75 (0.7)
American Indian or Alaska Native 46 (0.4)
Native Hawaiian or other Pacific Islander 10 (0.1)
Multiple 290 (2.6)
Other/unknown 368 (3.3)
Choose not to report 95 (0.9)
European Union—area of origin 3,407 (23.3)
Western Europe 2,927 (85.9)




Choose not to report 69 (2.0)
Age at diagnosis (years)§ 35.4 (11.2)
Age at first symptoms (years)¶ 32.6 (11.4)
MS subtype, n (%)‡
Relapsing remitting 8,708 (59.5)
Secondary progressive 2,504 (17.1)
Progressive relapsing 1,247 (8.5)
Primary progressive 1,100 (7.5)
Missing 1,084 (7.4)







Dimethyl fumarate 1,966 (13.4)













Ability to participate in social roles 47.3 (8.0)
Anxiety 51.1 (9.4)
Cognitive functioning 46.2 (9.0)
(Continued)
TABLE 4 | Continued
Characteristic* Value
Depression 47.3 (8.0)
Emotional behavioral dyscontrol†† 50.6 (9.9)
Positive affect or well-being†† 52.7 (7.2)




Lower extremity function 46.7 (11.2)
Sleep 52.7 (10.2)
Upper extremity function 45.4 (9.6)
DMT, disease-modifying therapy; MS, multiple sclerosis; Neuro-QoL, Quality of Life in
Neurological Disorders.




n = 11,567, ‡n = 14,643, §n = 13,904, ¶n = 14,236.
# Includes interferon beta-1a, interferon beta-1b, interferon beta-other, and
peginterferon beta-1a.
**Mean (SD) score reference value 50 (10); n = 11,827.
variables as percentages. Between-group differences were
assessed using t tests and chi-square (χ2) tests, as appropriate.
To test whether MS PATHS is more diverse than typical
phase 3 clinical trials in MS, the characteristics of patients with
relapsing–remitting MS (RRMS) enrolled in MS PATHS were
compared with patients with RRMS pooled from six phase 3
randomized controlled clinical trials (RCTs) sponsored by Biogen
(25–29). Comparisons of patients fromMS PATHS vs. the pooled
RCTs were made using Wilcoxon rank-sum tests and Pearson
χ
2 tests. Standardized mean or proportion differences (i.e., effect
sizes) were also calculated. C statistics for membership (30) and
predicted probability (i.e., propensity score) distributions were
estimated using multivariable logistic regression models to assess
overall baseline characteristics (i.e., case–mix) similarity. To
assess the extent of overlap in the two populations (MS PATHS vs.
RCTs), 1:1 propensity score matching (31) was performed based
on a 5:1 greedy match algorithm (32). Comparisons between the
matched sample characteristics were made using McNemar’s test
or Wilcoxon signed rank test. Effect sizes and C statistics for
membership were also reported.
To assess heterogeneity in terms of assessment frequency,
separate Kaplan–Meier plots were created for each center,
describing the time (months) between assessments.
Heterogeneity at the level of the healthcare institution was
tested using log-rank tests. Separate analyses were conducted for
MSPT and MRI assessments.
RESULTS
MS PATHS Patient Population
As of August 5, 2019, 16,568 patients from 10 participating
institutions in the United States (n= 7) and the European Union
(n = 3) agreed to share their clinical data, representing 71.4% of
patient census seen in theMS clinics within the network. As of the
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TABLE 5 | Neuroperformance scores at initial assessment.
Mean (SD) parameter All RRMS SPMS PRMS PPMS F test,
p value
















































PPMS, primary progressive multiple sclerosis; PRMS, progressive relapsing multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive
multiple sclerosis.
cutoff date for the data included in this manuscript, the number
of withdrawals was 158 (0.95%) and ranged from 0.12 to 2.91% of
participants across the sites.
Of 16,568 enrolled patients, 14,643 patients completed at least
one MSPT assessment; the characteristics at the time of initial
MSPT assessment for these patients are shown in Table 4. Mean
(SD) age was 47.0 (12.4) years and the population was largely
female [n = 10,712 (73.2%)] and predominantly white, although
the absolute number of non-white participants is substantial.
Mean (SD) Neuro-QoL T-scores ranged from 45.4 (9.6) to
52.7 (10.2).
At their initial MSPT assessment, 69.6% of 14,643 patients
reported the use of a DMT. The most frequently reported DMTs
were dimethyl fumarate, glatiramer acetate, and fingolimod.
DMT use was highest in patients with RRMS [6,495 (74.6%)]
compared with patients with progressive MS [1,662 (66.4%)
secondary progressive, 540 (49.1%) primary progressive, and 806
(64.6%) progressive relapsing; χ2 = 349.5; p < 0.0001].
The neuroperformance scores at initial assessment are
summarized in Table 5. Patients with RRMS performed better
on neuroperformance testing compared with patients with
progressive disease.
Assessment Completion Rates and Data
Volume
The initial completion rates for the MSPT component modules
ranged from 56.5% (8,277/14,643; contrast sensitivity test) to
100.0% (14,643/14,643;MyHealthmodule;Table 6).Missing data
resulted from the coordinator disabling the module for patients
unable or unwilling to complete the test or the patient canceling
the test themselves. Longitudinal MSPT data were available
for 72.7% (10,640/14,643) of patients (Table 7). The average
patient contributed 15.6 person-months of follow-up (95% CI:
15.5–15.8); overall, 166,158 person-months of follow-up have
been accumulated.
A total of 14,414 MRI studies were collected from 8,364
unique patients, including 3,822/8,364 (45.7%) patients with
longitudinal MRI data (Table 7). Of the 14,414 MRI studies
received, 281 (2.0%) were rejected for being incomplete or not
acquired using standardized sequence parameters. Of 14,643








Processing speed test 14,643 13,250 (90.5) 1,393 (9.5)
Contrast sensitivity test 14,643 8,277 (56.5) 6,366 (43.5)
Manual dexterity test 14,643 11,829 (80.8) 2,814 (19.2)
Walking speed test 14,643 12,152 (83.0) 2,491 (17.0)
Neuro-QoL
†
14,643 11,827 (80.8) 2,816 (19.2)
MyHealth‡ 14,643 14,643 (100.0)
MSPT, Multiple Sclerosis Performance Test; Neuro-QoL, Quality of Life in Neurological
Disorders. *MSPT assessments taken on the same day are combined into a single record.
†A computer-adaptive quality-of-life measure included with the MSPT.
‡A structured patient questionnaire that records demographics, health history, use of
multiple sclerosis disease-modifying therapy, and multiple sclerosis status.
patients with at least one MSPT assessment, 7,622 (52.1%) had
at least one standardized 3T MRI.
A one-time genetic sample was collected from 6,320 patients.
Other blood samples have been collected at a total of
10,223 biobanking visits from 6,581 unique patients, including
2,584/6,581 (39.3%) with a longitudinal sample collected
(Table 7). The 10,223 biobanking visits represent 129,986
individual samples received in the central laboratory. A total
of 265 (0.2%) samples were rejected after the initial quality
control checks.
Heterogeneity Observed Across Sites
After completing their initial MSPT, 64% and 81% of patients
in MS PATHS completed a follow-up MSPT within 12 and
24 months, respectively (Figure 1A). The median time to
complete a follow-up MSPT was ∼7.4 months after the initial
MSPT. The median time to complete a follow-up MSPT
varied considerably among the participating healthcare
institutions, ranging from 3 to 13 months (Figure 1B;
χ
2 = 2,575; p < 0.0001).
After completing their initial standardized 3T brain MRI,
30% and 58% of patients in MS PATHS completed a follow-up
standardized 3T brainMRI within 12 and 24months, respectively
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TABLE 7 | MS PATHS data volume (N = 16,568).
Assessment Total assessments ≥1, n (%) ≥2, n (%) ≥3, n (%) ≥4, n (%)
MSPT 41,187 14,643 (100) 10,640 (72.7) 7,038 (48.1) 4,332 (29.6)
Median (IQR) duration since first assessment (days) 448 (282–650) 553 (390–725) 609 (478–763)
Brain MRI 14,414 8,364 (100) 3,822 (45.7) 1,510 (18.1) 470 (5.6)
Median (IQR) duration since first assessment (days) 469 (350–715) 721 (565–834) 859 (721–1004)
Biobanking 10,223 6,581 (100) 2,584 (39.3) 836 (12.7) 196 (3.0)
Median (IQR) duration since first assessment (days) 364 (224–483) 546 (421–637) 658 (609–736)
IQR, interquartile range; MRI, magnetic resonance imaging; MS PATHS, Multiple Sclerosis Partners Advancing Technology and Health Solutions; MSPT, Multiple Sclerosis
Performance Test.
(Figure 2A). The median time between the two standardized 3T
brain MRIs was ∼18 months. The median time to complete a
follow-up standardized 3T brainMRI varied considerably among
the participating healthcare institutions, ranging from 12 to 24
months (Figure 2B; n = 721; p < 0.0001). In four institutions,
half of the patients had not yet had a second standardized 3T
brain MRI.
DMT use varied across the participating sites, in terms of both
whether or not a patient was treated with a DMT (χ2 = 163.3;
p < 0.0001) and which DMT was prescribed (χ2 = 2,584.6; p <
0.0001; Table 8).
Heterogeneity Relative to Phase 3MS RCTs
The patients in MS PATHS were significantly older and had
a longer disease duration than the patients from the pooled
RCTs (Table 9). In addition, the proportion of patients with no
relapses in the last 12 months was higher in MS PATHS (54.4%)
than in the pooled RCTs (1.4%). The logistic regression models
predicting membership in MS PATHS resulted in a C statistic of
0.91 vs. the pooled RCTs. A C statistic of 1.0 indicates no overlap;
0.91 indicates that RCT patients were substantially distinct from
patients inMS PATHS. Propensity score 1:1matching of the 8,708
patients with RRMS inMS PATHS and 6,574 patients with RRMS
in the pooled RCTs yielded 1,922 patients from each sample that
were able to be matched (Table 9).
Research Utilization of LHS Data
The governing subcommittee has approved 58 data use requests
and one sample use request. Based on these requests, 78
conference abstracts and manuscripts have been published. Two
National Institutes of Health grants have been funded.
DISCUSSION
The Institute of Medicine, a member of the US National
Academies, recommended foundational elements for an LHS
(10) as an approach to address recognized challenges, including
the need for consistent quality and efficiency, in theUS healthcare
system. These challenges are also recognized by healthcare
systems and regulatory bodies outside of the United States such
as the European Medicines Agency (2, 4, 33–35). As the first
LHS in MS, MS PATHS was designed to incorporate each of the
foundational elements outlined in the introduction.
There were three initial observations from MS PATHS.
The first relates to the characteristics of patients with MS.
Although the patients in MS PATHS demonstrate demographic
and disease characteristics typical of other large MS cohorts,
the clinical characteristics from patients with RRMS in MS
PATHS are partially non-overlapping with the patients enrolled
in clinical trials (25–29), thus reflecting a broader population.
The patients in MS PATHS exhibited a broader range of ages,
disability levels, disease duration, and DMT use, presumably
because MS PATHS aims to enroll all patients with a
diagnosis of MS, including clinically isolated syndrome, with
no additional inclusion or exclusion criteria (e.g., requiring
a relapse in the past 12 months, as is typically required
in pivotal RCTs). MS PATHS is more racially diverse than
previously reported trials; white patients make up 79.5% of the
US MS PATHS population in comparison with 93.7% of the
oral DMT clinical trial study population (36). The minimal
inclusion criteria and the robust enrollment rates suggest
that studies using the MS PATHS population will generate
data that will be more generalizable than data from clinical
trials, in which enrollment is more selective. It is also likely
that patient characteristics obtained from MS PATHS will be
more representative of the broader MS population than data
from registries where a smaller subset of patients from a
clinical practice in one location is selected for inclusion in the
cohort (37).
The second observation is the demonstrated feasibility
of real-time quantitative patient phenotyping as part of
clinical practice. As of August 5, 2019, 88.4% of patients
who gave permission for their clinical data to be used for
research have completed at least one self-administered
neuroperformance assessment. Also, standardized MRI
acquisition sequences were incorporated into clinical brain
MRI protocols, with 98% of scans passing the quality
control assessments.
The third observation relates to the variability in practice
patterns observed across participating healthcare institutions.
We observed a significant inter-institution variability in the
rate of return for follow-up and the average interval between
assessments captured in MS PATHS, indicating that there is no
uniform standard for visit frequency in the network. Follow-up
interval is important when determining outcomes because visit
frequency may influence observed event frequency, depending
on how the information is captured. For example, individuals
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FIGURE 1 | Probability of completing a follow-up Multiple Sclerosis Performance Test (MSPT; as a function of months between the initial MSPT and completing the
second MSPT), (A) overall and by (B) Multiple Sclerosis Partners Advancing Technology and Health Solutions center.
with MS may not always present to the physician during
a relapse (38).
MS PATHS has experienced challenges and learnings during
the initial implementation, including:
(1) Creating trust in an academic–industry collaboration: The
initial collaborators were excited about the vision of MS PATHS;
however, there were questions on how to build trust in a multi-
party collaboration with a biopharmaceutical company. The
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FIGURE 2 | Probability of completing a follow-up standardized magnetic resonance imaging on a Siemens 3T scanner, (A) overall and (B) by individual Multiple
Sclerosis Partners Advancing Technology and Health Solutions center.
initial collaborators recognized that a transparent governance
process would be key to engender trust among the participants
and in the scientific community at large. All parties quickly
aligned on a vision of using the LHS concept to generate evidence
to improve outcomes for patients with MS as well as the guiding
principles (Table 1). The governance model was then developed
over the course of six all-day meetings to enable all parties to
fulfill the shared vision and operate by the guiding principles.
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TABLE 8 | Distribution of DMT use by participating healthcare institutions at initial assessment*.
Institution






















Alemtuzumab 230 (1.6) 12 (0.1) 3 (0.0) 4 (0.0) 103 (0.7) 19 (0.1) 14 (0.1) 4 (0.0) 28 (0.2) 0 (0.0) 43 (0.3)
Azathioprine 6 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.0) 2 (0.0) 2 (0.0)
Cyclophosphamide 2 (0.0) 0 (0.0) 1 (0.0) 0 (0.0) 0 (0.0) 1 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Daclizumab 37 (0.3) 1 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.0) 0 (0.0) 4 (0.0) 0 (0.0) 6 (0.0) 24 (0.2)
Dimethyl fumarate 1,966 (13.4) 152 (1.0) 159 (1.1) 67 (0.5) 179 (1.2) 641 (4.4) 104 (0.7) 317 (2.2) 115 (0.8) 104 (0.7) 128 (0.9)
Fingolimod 1,645 (11.2) 148 (1.0) 138 (0.9) 70 (0.5) 241 (1.6) 484 (3.3) 74 (0.5) 62 (0.4) 101 (0.7) 105 (0.7) 222 (1.5)
Glatiramer acetate 1,760 (12) 324 (2.2) 63 (0.4) 88 (0.6) 159 (1.1) 395 (2.7) 95 (0.6) 330 (2.3) 158 (1.1) 39 (0.3) 109 (0.7)
Immunoglobulin G 12 (0.1) 0 (0.0) 3 (0.0) 0 (0.0) 2 (0.0) 6 (0.0) 1 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Interferon beta-1a 1,088 (7.4) 171 (1.2) 50 (0.3) 44 (0.3) 67 (0.5) 295 (2.0) 41 (0.3) 129 (0.9) 225 (1.5) 31 (0.2) 35 (0.2)
Interferon beta-1b 245 (1.7) 12 (0.1) 10 (0.1) 11 (0.1) 13 (0.1) 13 (0.1) 9 (0.1) 14 (0.1) 130 (0.9) 16 (0.1) 17 (0.1)
Interferon beta-other 16 (0.1) 2 (0.0) 4 (0.0) 0 (0.0) 2 (0.0) 6 (0.0) 0 (0.0) 2 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Methotrexate 27 (0.2) 1 (0.0) 2 (0.0) 0 (0.0) 0 (0.0) 21 (0.1) 0 (0.0) 2 (0.0) 0 (0.0) 1 (0.0) 0 (0.0)
Mitoxantrone 6 (0.0) 0 (0.0) 1 (0.0) 0 (0.0) 2 (0.0) 1 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.0) 1 (0.0)
Mycophenolate mofetil 24 (0.2) 3 (0.0) 1 (0.0) 0 (0.0) 2 (0.0) 13 (0.1) 0 (0.0) 5 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Natalizumab 1,384 (9.5) 139 (0.9) 155 (1.1) 53 (0.4) 271 (1.9) 263 (1.8) 65 (0.4) 217 (1.5) 95 (0.6) 34 (0.2) 92 (0.6)
Ocrelizumab 748 (5.1) 27 (0.2) 60 (0.4) 64 (0.4) 140 (1.0) 173 (1.2) 21 (0.1) 108 (0.7) 23 (0.2) 27 (0.2) 105 (0.7)
Ofatumumab 1 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Peginterferon beta-1a 159 (1.1) 14 (0.1) 15 (0.1) 17 (0.1) 5 (0.0) 26 (0.2) 5 (0.0) 38 (0.3) 22 (0.2) 7 (0.0) 10 (0.1)
Rituximab 272 (1.9) 45 (0.3) 67 (0.5) 18 (0.1) 18 (0.1) 15 (0.1) 7 (0.0) 65 (0.4) 31 (0.2) 3 (0.0) 3 (0.0)
Teriflunomide 562 (3.8) 54 (0.4) 39 (0.3) 41 (0.3) 85 (0.6) 76 (0.5) 39 (0.3) 42 (0.3) 104 (0.7) 28 (0.2) 54 (0.4)
Other 1,077 (7.4) 139 (0.9) 74 (0.5) 20 (0.1) 110 (0.8) 298 (2.0) 68 (0.5) 98 (0.7) 103 (0.7) 58 (0.4) 109 (0.7)
None 3,341 (22.8) 337 (2.3) 214 (1.5) 75 (0.5) 317 (2.2) 922 (6.3) 234 (1.6) 395 (2.7) 465 (3.2) 159 (1.1) 223 (1.5)
Missing 35 (0.2) 0 (0.0) 2 (0.0) 0 (0.0) 5 (0.0) 20 (0.1) 0 (0.0) 1 (0.0) 5 (0.0) 0 (0.0) 2 (0.0)
DMT, disease-modifying therapy.
*Likelihood ratio (DMT × site) χ2 = 2,584.6; p < 0.0001.
(2) Aligning on which data to collect and how to standardize
data collection: Given the broad research goals of MS PATHS,
the potential data to collect were vast. In the initial planning
discussions, it became clear that standardizing and collecting
all potential data would not fit into the clinical workflow.
Data were prioritized in terms of time and utility. The
goal was to keep MSPT administration no longer than
30minutes for the average patient with MS, keep the brain
MRI total scan time unchanged, and add no additional time
to a clinician’s clinical documentation. Any suggested patient-
reported question or scale was weighed in terms of time
to complete and its potential utility for clinical care and
research. Implementing axial reconstruction of the standardized
three-dimensional sequences allowed radiologists/neurologists
to view scans as they normally would without the need for
duplicative MRI acquisitions. Also, collaborating with Siemens
Healthineers allowed the sequences to be optimized based on
feedback from MS PATHS radiologists to enable broad adoption
in the network.
(3) Implementation of common health IT platforms:
Generating data in real time for clinical decision-making and
providing pseudonymized data for research involved major
technical challenges. We started with a basic design of a health
information exchange platform and iterated after receiving
feedback from key IT stakeholders at the founding institutions.
Because IT architecture is different in each medical center,
interfaces for the IT platforms need to be customized for
each medical center to ensure compatibility and adherence to
security requirements. The current implementation maintains
consistent data handling and processing across the network
but flexes to allow for variability in the interfaces and whether
a push or pull model is optimal for each individual medical
center. This type of model was aided by the increasing adoption
of common healthcare data standards across healthcare
in general.
(4) Ensuring compliance with US and EU data privacy
regulations: MS PATHS was designed to be both HIPAA and
GDPR compliant. In MS PATHS, patient data are only shared
for research purposes, with patient consent. Trusted third parties
serve as intermediaries to remove patient identifiers before the
data are aggregated for research under appropriate contractual
arrangements. Garnering acceptance and approval from amyriad
of stakeholders at each institution is equally as important as
a sound program design. MS PATHS has shown that with a
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TABLE 9 | Demographic and clinical characteristics of patients with RRMS in MS PATHS and Biogen phase 3 RCTs (25–29).
Unmatched population Propensity score-matched population
Variable* MS PATHS RCTs Cohen’s MS PATHS RCTs Cohen’s
d value d value
N 8,708 6,574 1,922 1,922
Age (years) 45.0 (12.2) 37.4 (8.9) −0.71 40.7 (11.3) 40.3 (8.7) −0.04
Male (%) 23.9 28.3 0.10 25.4 26.4 0.02
Body mass index (kg/m2 ) 28.9 (7.0) 25.1 (5.4) −0.60 27.9 (6.3) 27.8 (6.8) −0.01
MS duration (years) 11.3 (9.0) 4.8 (5.0) −0.90 7.2 (6.3) 7.1 (6.3) −0.01
Manual dexterity test/9-Hole Peg
Test (seconds)†
25.9 (5.9) 22.1 (6.1) −0.63 25.1 (4.7) 25.3 (8.0) 0.03
25-foot walking speed test/Timed
25-Foot Walk (seconds)†
6.6 (3.2) 6.4 (4.5) −0.04 6.5 (3.0) 6.5 (3.3) 0.01
Number of relapses in the past 12 months
NA 0.8 4.6 0.24 1.9 2 0.01
0 54.4 1.4 −1.46 4.8 4.8 0
1 23.8 58.8 0.76 54.9 54.1 −0.02
2 12.6 29 0.41 26.5 26.7 0
≥3 8.4 6.1 −0.09 11.8 12.4 0.02
MS, multiple sclerosis; MS PATHS, Multiple Sclerosis Partners Advancing Technology and Health Solutions; NA, not applicable; RCT, randomized clinical trial; RRMS, relapsing-remitting
multiple sclerosis.
*Data are reported as mean (SD) or n (%) for continuous and categorical variables, respectively. Cohen’s d values represent standardized mean or proportion differences (i.e., effect
sizes). An absolute value of % d >10 is considered as clinically meaningful.
†
The manual dexterity test and 25-foot walking speed test were administered in MS PATHS and the 9-Hole Peg Test and Timed 25-Foot Walk were administered in the RCTs.
sound program design, stakeholder engagement, and patient
permission, data aggregation is feasible to conduct under both
HIPAA and GDPR.
(5) Enabling efficient data sharing: Our chosen hub-and-
spoke data sharing model simplified contractual relationships in
MS PATHS. Each healthcare institution negotiated directly with
Biogen rather than having to enter into amulti-lateral negotiation
for the initial contract and any subsequent amendments. All
stakeholders acknowledged the logistical benefits of this model.
However, it required key clauses on the scope of data sharing,
data permissions, and intellectual property to be uniform
across all contracts and informed consent forms and for all
parties to be comfortable that we could not accommodate
one-off deviations if we were to maintain an effective
hub-and-spoke model.
(6) Re-engineering of clinical workflows involved all aspects
of clinic operations: One example of how MS clinics needed
to change their operations was the incorporation of the MSPT
into the clinical workflow. This necessitated designating space in
the clinic as a MSPT testing area, training staff on the MSPT,
introducing MS patients to a new aspect of their visit, and
adjusting patient arrival times whether formally through a new
appointment time or reminders to arrive 30min before their
scheduled visit with their healthcare provider. The workflow
challenges differed somewhat for implementing the MSPT,
implementing the standardized MRI protocol, and research
workflows such as biobanking. Enthusiasm for the LHS tenets
and the project sustained commitment from academic and
industry project leaders, overcoming a myriad of challenges. The
network investigators also committed to sharing best practices
through conference calls, investigator meetings, and site visits.
For example, an early MSPT implementation insight shared
across the network was that patients generally have a better
testing experience if they take the test without staff, a family
member, or a caregiver by their side.
(7) Real-life experience highlighted gaps in original technical
assumptions: Some design issues that have emerged and are
being corrected include issues with MSPT functionality (e.g.,
lower-than-expected contrast sensitivity test completion rates)
and issues with optimizing data collection methods for certain
variables (e.g., comorbidities, medication start/stop dates).
Among the advantages of an academic and industry partnership
model are the real-time and continuous feedback, re-assessment,
and refinement of data gathering and overall strategy that
facilitate continuous improvement. One example of this feedback
loop is the creation of a MS SmartForm by one of the MS PATHS
institutions that is freely available in EPIC foundation to all
EPIC users. This SmartForm will facilitate the standardization of
key MS-related variables such as relapses and disease-modifying
therapy start/stop dates to primarily aid clinical care, but with
the secondary benefit of improving data quality for research.
The US MS PATHS centers are currently in various stages of
SmartForm implementation, while we are coordinating with the
EU MS PATHS centers to harmonize as much as possible.
(8) Incorporating the voice of the patient: Patients have always
been identified as a key stakeholder in MS PATHS. During the
design phase, the investigators engaged a local patient advisory
group, when available, on theMS PATHS concept. TheMSPTwas
designed to facilitate the voice of the patient being incorporated
into the clinical visit through the neuroperformance modules
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and 12 domains of quality-of-life as assessed by the Neuro-QoL.
Prior to the initial deployment of the MSPT in MS PATHS,
qualitative feedback was obtained by the patients in an initial
usability study (11). However, there is still more to be done to
engage patients and complete the feedback loop as envisioned in
a LHS (10). To start, the network is working to generate regular
patient newsletters that provide updates on MS PATHS and
summarize recent research presented at conferences or published
in journals. Each MS center will provide these updates via their
routine patient communication channels. We are also working
on an updated publicly facing website that would also have
this information.
(9) Moving from clinical implementation to clinical decision-
making: Our efforts to date have been focused on the initial
implementation and data collection as highlighted in this paper.
The network is now shifting focus to evidence generation that
will enable the data collected in MS PATHS to be used more
routinely for clinical decision-making. Key next topics include
understanding clinical cutoffs for the MSPT and MRI metrics,
looking at practice heterogeneity across the network to identify
best practices, and exploring feedback loops for investigators to
more easily use the data for quality improvement.
Despite the promise of this research, there are limitations to be
considered. Data missingness may be non-random. For example,
patients with more disability may be less likely to have an MRI
or complete the MSPT. The participating centers are referral
centers and may not fully represent broader MS populations.
For example, the rates of patients with progressive disease on
a DMT may be higher than expected, and incorporation of
the SmartForm data may provide additional insight. Still the
MS PATHS population represents an improvement over the
populations included in clinical trials as it is more racially and
clinically diverse.
Another limitation is related to the restriction of standardized
MRI studies to Siemens 3T scanners. This was intentional in
order to remove scanner and manufacturer variability from the
derived metrics as the initial step in delivering point-of-care
MRI-basedmetrics to the clinician. As such, the time to follow-up
MRI does not take into account the MRI exams acquired within
each institution on non-Siemens 3T MRI scanners or using
different (non-standardized) acquisition sequences or an MRI
obtained outside the healthcare institution. Therefore, differences
in MRI follow-up time between centers may reflect variations in
the use of Siemens 3T scanners and variation in the percentage
of patients who obtain MRI exams outside of the healthcare
institution. A few participating centers image their patients with
MS exclusively on Siemens 3T scanners, while others use a wide
variety of scanner types across internal and external imaging
facilities. Translation of the imaging methods to non-Siemens 3T
scanners is planned.
The initial implementation of MS PATHS has been successful
overall, although we are continuously optimizing aspects of
our operations. We anticipate its value to grow with time as
large-scale, longitudinal, and multidimensional quantitative data
accumulate. These data will potentially drive new insights and aid
in the development and the validation of new technologies. In
particular, incorporating point-of-care quantitative MRI-based
metrics in clinical practice has the potential to transform
precision medicine to the same degree that MRI-based metrics
have advanced clinical trials.
Another important direction for future work in MS PATHS
is defining individual patient outcomes using quantitative
standardized data. As MS PATHS data accumulate, it may be
possible to define complete MS disease control or actionable
change based on quantitative monitoring. Further, in the future,
decision support based on advanced analytic methods could
help neurologists care for individuals with MS in the context of
a large number of DMTs and other therapeutic choices. Data
accumulated in MS PATHS could support the development of
predictive models and decision support systems.
The LHS concept, exemplified byMS PATHS, could accelerate
translational research inMS as evidenced by the number of active
proposals and grant approvals. Tens of thousands of patients may
be required to unravel the biological basis for MS heterogeneity
and develop personalized medicine based on individual patient
characteristics. Using quantitative data derived from clinical,
imaging, and laboratory assessments generated during patient
care could drastically reduce the cost of, and thus make feasible,
such translational research studies.
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